Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manuela Schmidinger

Showing results (41-50 of 112) with videos related to

Pageof 12
Sort By:
Expert Opinion on Drug Safety|March 20, 2014
Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studiesSergio Bracarda, Daniel Castellano, Giuseppe Procopio, et al.
Pathology Oncology Research : POR|July 30, 2017
HER2 and TOP2A Gene Amplification and Protein Expression in Upper Tract Urothelial CarcinomasKlaus Aumayr, Tobias Klatte, Barbara Neudert, et al.
Clinical Genitourinary Cancer|June 27, 2020
Real-world Experience With Sunitinib Treatment in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to Risk ScoreManuela Schmidinger, Camillo Porta, Stephane Oudard, et al.
Histopathology|April 8, 2015
Evaluation of tyrosine kinase receptors in brain metastases of clear cell renal cell carcinoma reveals cMet as a negative prognostic factorAna-Iris Schiefer, Ildiko Mesteri, Anna S Berghoff, et al.
Wiener Klinische Wochenschrift|May 20, 2015
War and peace? The oncologic and the palliative care perspective on personalized cancer treatment in a patient with advanced cancerEva K Masel, Sophie Schur, Doris Posch, et al.
Clinical & Experimental Metastasis|August 8, 2025
Targeting metabolic and epigenetic reprogramming in metastatic fumarate hydratase-deficient renal cell carcinomaNadja Kührer, Irene Huebner-Resch, Roman Mayr, et al.
Expert Review of Anticancer Therapy|January 4, 2017
How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinomaSergio Bracarda, Sylvie Negrier, Jochen Casper, et al.
Haematologica|May 26, 2018
Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancerElla Grilz, Oliver Königsbrügge, Florian Posch, et al.
Cancer Letters|January 28, 2009
Synergistic effect of Sorafenib and Sunitinib with Enzastaurin, a selective protein kinase C inhibitor in renal cell carcinoma cell linesUrsula Maria Vogl, Walter Berger, Michael Micksche, et al.
Cancer Treatment Reviews|February 12, 2020
Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugsStefano Fogli, Camillo Porta, Marzia Del Re, et al.
Pageof 12

Showing results (41-50 of 112) with videos related to

Sort By:
Pageof 12
Expert Opinion on Drug Safety|March 20, 2014
Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studiesSergio Bracarda, Daniel Castellano, Giuseppe Procopio, et al.
Pathology Oncology Research : POR|July 30, 2017
HER2 and TOP2A Gene Amplification and Protein Expression in Upper Tract Urothelial CarcinomasKlaus Aumayr, Tobias Klatte, Barbara Neudert, et al.
Clinical Genitourinary Cancer|June 27, 2020
Real-world Experience With Sunitinib Treatment in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to Risk ScoreManuela Schmidinger, Camillo Porta, Stephane Oudard, et al.
Histopathology|April 8, 2015
Evaluation of tyrosine kinase receptors in brain metastases of clear cell renal cell carcinoma reveals cMet as a negative prognostic factorAna-Iris Schiefer, Ildiko Mesteri, Anna S Berghoff, et al.
Wiener Klinische Wochenschrift|May 20, 2015
War and peace? The oncologic and the palliative care perspective on personalized cancer treatment in a patient with advanced cancerEva K Masel, Sophie Schur, Doris Posch, et al.
Clinical & Experimental Metastasis|August 8, 2025
Targeting metabolic and epigenetic reprogramming in metastatic fumarate hydratase-deficient renal cell carcinomaNadja Kührer, Irene Huebner-Resch, Roman Mayr, et al.
Expert Review of Anticancer Therapy|January 4, 2017
How clinical practice is changing the rules: the sunitinib 2/1 schedule in metastatic renal cell carcinomaSergio Bracarda, Sylvie Negrier, Jochen Casper, et al.
Haematologica|May 26, 2018
Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancerElla Grilz, Oliver Königsbrügge, Florian Posch, et al.
Cancer Letters|January 28, 2009
Synergistic effect of Sorafenib and Sunitinib with Enzastaurin, a selective protein kinase C inhibitor in renal cell carcinoma cell linesUrsula Maria Vogl, Walter Berger, Michael Micksche, et al.
Cancer Treatment Reviews|February 12, 2020
Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugsStefano Fogli, Camillo Porta, Marzia Del Re, et al.
Pageof 12